{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:35:39Z","timestamp":1774877739316,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"Objective<\/jats:title>Pituitary neuroendocrine corticotroph tumors commonly cause Cushing\u2019s disease (CD) that results from increased adrenocorticotropic hormone (ACTH) secretion by the pituitary tumor and consequent increase of cortisol levels in blood. However, in some patients, corticotroph tumors remain clinically non-functioning. Cortisol secretion is regulated by the hypothalamic\u2013pituitary\u2013adrenal axis and includes a negative feedback between cortisol and ACTH secretion. Glucocorticoids reduce ACTH level both by hypothalamic regulation and acting on corticotrophs via<\/jats:italic> glucocorticoid (GR) and mineralocorticoid (MR) receptors. The aim of the study was to determine the role of GR and MR expression at mRNA and protein levels in both functioning and silent corticotroph tumors.<\/jats:p><\/jats:sec>Methods<\/jats:title>Ninety-five patients were enrolled, including 70 with CD and 25 with silent corticotroph tumors. Gene expression levels of NR3C1<\/jats:italic> and NR3C2<\/jats:italic> coding for GR and MR, respectively, were determined with qRT-PCR in the two tumor types. GR and MR protein abundance was assessed with immunohistochemistry.<\/jats:p><\/jats:sec>Results<\/jats:title>Both GR and MR were expressed in corticotroph tumors. Correlation between NR3C1<\/jats:italic> and NR3C2<\/jats:italic> expression levels was observed. NR3C1<\/jats:italic> expression was higher in silent than in functioning tumors. In CD patients NR3C1<\/jats:italic> and NR3C2<\/jats:italic> levels were negatively correlated with morning plasma ACTH levels and tumor size. Higher NR3C2<\/jats:italic> was confirmed in patients with remission after surgery and in densely granulated tumors. Expression of both genes and GR protein was higher in USP8<\/jats:italic>-mutated tumors. Similar relationship between USP8<\/jats:italic> mutations and expression levels were observed in analysis of silent tumors that also revealed a negative correlation between GR and tumor size and higher NR3C1<\/jats:italic> expression in densely granulated tumors.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Although the associations between gene\/protein expression and patients clinical features are not strong, they consistently show an evident trend in which higher receptor expression corresponds to more favorable clinical characteristics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1124646","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T05:32:45Z","timestamp":1680067965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing\u2019s disease and silent corticotroph tumors"],"prefix":"10.3389","volume":"14","author":[{"given":"Paulina","family":"Kober","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rusetska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata J.","family":"Mossakowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Maksymowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"P\u0119kul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Zieli\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Styk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Kunicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Dzia\u0142ach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Bujko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10014-021-00410-5","article-title":"Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms","volume":"38","author":"Inomoto","year":"2021","journal-title":"Brain Tumor Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-018-0864-8","article-title":"Silent corticotroph adenomas","volume":"21","author":"Ben-Shlomo","year":"2018","journal-title":"Pituitary"},{"key":"B3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0194","article-title":"USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status","volume":"181","author":"Bujko","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/ENDREV\/BNAA002","article-title":"Dynamics of ACTH and cortisol secretion and implications for disease","volume":"41","author":"Lightman","year":"2021","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00021","article-title":"Molecular mechanisms of glucocorticoid resistance in corticotropinomas: New developments and drug targets","volume":"11","author":"Ciato","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2022.100455","article-title":"Mineralocorticoid receptor and glucocorticoid receptor work alone and together in cell-type-specific manner: Implications for resilience prediction and targeted therapy","volume":"18","author":"Daskalakis","year":"2022","journal-title":"Neurobiol Stress"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00158","article-title":"Glucocorticoid and mineralocorticoid receptors in the brain: A transcriptional perspective","volume":"3","author":"Koning","year":"2019","journal-title":"J Endocr Soc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126469","article-title":"The role of glucocorticoid receptor in the pathophysiology of pituitary corticotroph adenomas","volume":"23","author":"Regazzo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.3.917","article-title":"Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus","volume":"83","author":"Huizenga","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052867","article-title":"Difference in miRNA expression in functioning and silent corticotroph pituitary adenomas indicates the role of miRNA in the regulation of corticosteroid receptors","volume":"23","author":"Mossakowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10030375","article-title":"Differential microRNA expression in USP8-mutated and wild-type corticotroph pituitary tumors reflect the difference in protein ubiquitination processes","volume":"10","author":"Bujko","year":"2021","journal-title":"J Clin Med"},{"key":"B13","article-title":"Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty","year":"1986","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0272","article-title":"The European registry on cushing\u2019s syndrome: 2-year experience. baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11102-017-0844-4","article-title":"Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review","volume":"21","author":"Langlois","year":"1234","journal-title":"Pituitary"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1227\/01.neu.0000429858.96652.1e","article-title":"A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas","volume":"73","author":"Jahangiri","year":"2013","journal-title":"Neurosurgery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-021-00333-y","article-title":"High-risk pituitary adenomas and strategies for predicting response to treatment","volume":"1","author":"Kontogeorgos","year":"2022","journal-title":"Hormones"},{"key":"B18","volume-title":"WHO classification of tumours of endocrine organs","author":"Osamura","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672178","article-title":"Clinical, biological, radiological pathological and immediate post-operative remission of sparsely and densely granulated corticotroph pituitary tumors: A retrospective study of a cohort of 277 patients with cushing\u2019s disease","volume":"12","author":"Rak","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.9.12.5305","article-title":"Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription","volume":"9","author":"Drouin","year":"1989","journal-title":"Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1444606","article-title":"Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in cushing disease","volume":"20","author":"Bilodeau","year":"2006","journal-title":"Genes Dev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0333","article-title":"Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B\/Nur77 orphan nuclear receptors and glucocorticoid receptor","volume":"19","author":"Martens","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/EN.2015-1265","article-title":"Rapid glucocorticoid feedback inhibition of ACTH secretion involves ligand-dependent membrane association of glucocorticoid receptors","volume":"156","author":"Deng","year":"2015","journal-title":"Endocrinol (United States)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K08E-186","article-title":"Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)- secreting pituitary tumors and silent corticotroph adenomas","volume":"56","author":"Tateno","year":"2009","journal-title":"Endocrine J Endocrine J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1028-0","article-title":"The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1\/3","volume":"56","author":"Righi","year":"2017","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1990.72.2.0262","article-title":"Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and cushing\u2019s disease","volume":"72","author":"Nagaya","year":"1990","journal-title":"J Neurosurg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0428","article-title":"Differential gene expression in ACTH -secreting and non-functioning pituitary tumors","volume":"157","author":"Tateno","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-10-0076","article-title":"Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with cushing\u2019s disease","volume":"163","author":"Raverot","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-008-9052-0","article-title":"Immunohistochemical analysis of 11-\u03b2-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical cushing\u2019s disease due to pituitary macroadenoma","volume":"19","author":"Ebisawa","year":"2008","journal-title":"Endocr Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.558593","article-title":"Clinical, laboratory, and treatment profiles of silent corticotroph adenomas that have transformed to the functional type: A case series with a literature review","volume":"11","author":"Zheng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-term survival after transformation of an adrenocorticotropic hormone\u2013secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.658429","article-title":"Cyclic cushing\u2019s syndrome \u2013 a diagnostic challenge","volume":"12","author":"\u015awi\u0105tkowska-Stodulska","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab257","article-title":"Glucocorticoid receptors are making a comeback in corticotroph tumorigenesis","volume":"163","author":"Theodoropoulou","year":"2022","journal-title":"Endocrinol (United States)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11111761","article-title":"The new genetic landscape of cushing\u2019s disease: Deubiquitinases in the spotlight","volume":"11","author":"Sbiera","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab167","article-title":"Effect of 3 NR3C1 mutations in the pathogenesis of pituitary ACTH adenoma","volume":"162","author":"Miao","year":"2021","journal-title":"Endocrinol (United States)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.4.1088","article-title":"Expression of glucocorticoid receptor gene isoforms in corticotropin- secreting tumors","volume":"82","author":"Dahia","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0990-x","article-title":"Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas","volume":"55","author":"Cassarino","year":"2017","journal-title":"Endocrine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00520.x","article-title":"Low level of glucocorticoid receptor messenger ribonucleic acid in pituitary adenomas manifesting cushing\u2019s disease with resistance to a high dose-dexamethasone suppression test","volume":"49","author":"Mu","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2004.12.013","article-title":"Colocalization of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus and hypothalamus","volume":"51","author":"Han","year":"2005","journal-title":"Neurosci Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.8.1496","article-title":"Colocalization of glucocorticoid and mineralocorticoid receptors in human bone","volume":"16","author":"Beavan","year":"2001","journal-title":"J Bone Mineral Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.09.011","article-title":"The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism","volume":"350","author":"Marzolla","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1991.260.2.c226","article-title":"Immunolocalization of gluco- and mineralocorticoid receptors in rabbit kidney","volume":"260","author":"Farman","year":"1991","journal-title":"Am J Physiol Cell Physiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1180479","article-title":"Parallel determination of mineralocorticoid and glucocorticoid receptors in T-and b-lymphocytes of human spleen","volume":"118","author":"Armanini","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-sun-463","article-title":"SUN-463 tumor shrinkage with preoperative relacorilant therapy in two patients with cushing disease due to pituitary macroadenomas","volume":"3","author":"Terzolo","year":"2019","journal-title":"J Endocr Soc"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-260","article-title":"Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells","volume":"9","author":"Chantong","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10253890.2018.1456526","article-title":"Mineralocorticoid and glucocorticoid receptor-mediated control of genomic responses to stress in the brain","volume":"21","author":"Mifsud","year":"2018","journal-title":"Stress"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1605246113","article-title":"Acute stress enhances heterodimerization and binding of corticosteroid receptors at glucocorticoid target genes in the hippocampus","volume":"113","author":"Mifsud","year":"2016","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1124646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T05:32:50Z","timestamp":1680067970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1124646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":49,"alternative-id":["10.3389\/fendo.2023.1124646"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1124646","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"article-number":"1124646"}}